ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Classement en actions
#19247
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Prix de l'action
$0.38122017
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$159.74M
Changement (1 jour)
2.58%
Changement (1 an)
-71.72%
Pays
CN
Échange ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Catégorie
Healthcare
Capitalisation boursière de ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Capitalisation boursière: $159.74M
En October 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. a une capitalisation boursière de $159.74M. Cela fait de ImmuneOnco Biopharmaceuticals (Shanghai) Inc. la 19247th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de ImmuneOnco Biopharmaceuticals (Shanghai) Inc. du 2023 au 2026
1541 par rapport au top 5 des plus populaires stocks
| Prix pour 1541 | L’actif B | La capitalisation boursière de B | Résultats | |
|---|---|---|---|---|
$12,534.39
$159.74M
|
$5.252T | +3,287,865.92% | ||
|
$11,935.22
$159.74M
|
$5.001T | +3,130,693.68% | ||
|
$9,966.12
$159.74M
|
$4.176T | +2,614,167.56% | ||
|
$9,469.52
$159.74M
|
$3.968T | +2,483,903.14% | ||
|
$6,770.56
$159.74M
|
$2.837T | +1,775,923.15% |
